The PATH Malaria Vaccine Initiative (MVI)
25
0
0
23
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.0%
2 terminated/withdrawn out of 25 trials
92.0%
+5.5% vs industry average
12%
3 trials in Phase 3/4
74%
17 of 23 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
Role: collaborator
Safety and Efficacy of NF135 CPS Immunization
Role: collaborator
Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F
Role: collaborator
Safety and Protective Efficacy of Pb(PfCS@UIS4)
Role: collaborator
Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine
Role: collaborator
Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults
Role: collaborator
Epidemiology Study of Malaria Transmission Intensity in Africa
Role: collaborator
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
Role: collaborator
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
Role: collaborator
Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults
Role: collaborator
Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults
Role: collaborator
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
Role: collaborator
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
Role: collaborator
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
Role: collaborator
Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children
Role: collaborator
Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants
Role: collaborator
Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1
Role: collaborator
Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
Role: collaborator
A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S
Role: collaborator
A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults
Role: collaborator